Ascentage Pharma Group International (NASDAQ:AAPG) Sets New 12-Month Low - What's Next?

Key Points

• Ascentage Pharma shares hit a new 52-week low, trading as low as $15.01 before recovering to around $18.97. The stock remains below its 50-day and 200-day moving averages.
• Analysts remain bullish despite the decline: the stock has an average “Buy” rating and a consensus price target of $46.43, with individual targets ranging from $40 to $48.
• Institutional interest has increased, including a 149.4% stake increase by UBS and new positions from HSBC Holdings and Citadel Advisors. Ascentage is a clinical-stage biotech developing small-molecule cancer therapies targeting apoptosis pathways.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) shares reached a new 52-week low during trading on Wednesday . The stock traded as low as $15.01 and last traded at $18.9690, with a volume of 501 shares. The stock had previously closed at $18.98.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Raymond James Financial reaffirmed a "buy" rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. B. Riley Financial assumed coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a "buy" rating and a $45.00 price target on the stock. Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They issued a "buy" rating and a $40.00 price objective for the company. Finally, BTIG Research reaffirmed a "buy" rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $46.43.

Ascentage Pharma Group International Stock Down 0.3%

The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. The business has a fifty day simple moving average of $18.09 and a two-hundred day simple moving average of $21.58.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of hedge funds have recently made changes to their positions in AAPG. UBS Group AG grew its stake in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company's stock valued at $716,000 after purchasing an additional 10,988 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International during the second quarter valued at about $391,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International during the third quarter valued at about $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source